BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rahaghi FF. Alpha-1 antitrypsin deficiency research and emerging treatment strategies: what's down the road? Ther Adv Chronic Dis 2021;12_suppl:20406223211014025. [PMID: 34408832 DOI: 10.1177/20406223211014025] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Barjaktarevic I, Campos M. Management of lung disease in alpha-1 antitrypsin deficiency: what we do and what we do not know. Ther Adv Chronic Dis 2021;12_suppl:20406223211010172. [PMID: 34408831 DOI: 10.1177/20406223211010172] [Reference Citation Analysis]
2 Butnariu LI, Țarcă E, Cojocaru E, Rusu C, Moisă ȘM, Leon Constantin MM, Gorduza EV, Trandafir LM. Genetic Modifying Factors of Cystic Fibrosis Phenotype: A Challenge for Modern Medicine. J Clin Med 2021;10:5821. [PMID: 34945117 DOI: 10.3390/jcm10245821] [Reference Citation Analysis]
3 Tejwani V, Stoller JK. The spectrum of clinical sequelae associated with alpha-1 antitrypsin deficiency. Ther Adv Chronic Dis 2021;12_suppl:2040622321995691. [PMID: 34408829 DOI: 10.1177/2040622321995691] [Cited by in F6Publishing: 3] [Reference Citation Analysis]